We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
-2.67%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$23.7B
AUM Growth
+$1.26B
Cap. Flow
+$2.43B
Cap. Flow %
10.25%
Top 10 Hldgs %
31.04%
Holding
1,328
New
56
Increased
716
Reduced
259
Closed
49

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$229M
2
MSFT icon
Microsoft
MSFT
+$208M
3
NVDA icon
NVIDIA
NVDA
+$198M
4
AMZN icon
Amazon
AMZN
+$197M
5
NOW icon
ServiceNow
NOW
+$193M

Sector Composition

Rank Sector Weight
1 Real Estate 35.46%
2 Technology 23.73%
3 Communication Services 9.02%
4 Consumer Discretionary 6.33%
5 Financials 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMLX icon
1201
Amylyx Pharmaceuticals
AMLX
$2.19B
$1K ﹤0.01%
266
ANNX icon
1202
Annexon
ANNX
$796M
$1K ﹤0.01%
352
AQST icon
1203
Aquestive Therapeutics
AQST
$452M
$1K ﹤0.01%
+500
New +$1.51K
ARCT icon
1204
Arcturus Therapeutics
ARCT
$165M
$1K ﹤0.01%
90
ATXS
1205
DELISTED
Astria Therapeutics
ATXS
$1K ﹤0.01%
186
AURA icon
1206
Aura Biosciences
AURA
$725M
$1K ﹤0.01%
165
AVIR icon
1207
Atea Pharmaceuticals
AVIR
$370M
$1K ﹤0.01%
242
BCYC
1208
Bicycle Therapeutics
BCYC
$269M
$1K ﹤0.01%
103
CDXS icon
1209
Codexis
CDXS
$158M
$1K ﹤0.01%
269
CRGX
1210
DELISTED
CARGO Therapeutics
CRGX
$1K ﹤0.01%
152
CRMD icon
1211
CorMedix
CRMD
$564M
$1K ﹤0.01%
200
CRVS icon
1212
Corvus Pharmaceuticals
CRVS
$1.1B
$1K ﹤0.01%
+400
New +$1.88K
DSGN icon
1213
Design Therapeutics
DSGN
$751M
$1K ﹤0.01%
+350
New +$1.67K
ERAS icon
1214
Erasca
ERAS
$6.15B
$1K ﹤0.01%
1,074
ESPR
1215
DELISTED
Esperion Therapeutics
ESPR
$1K ﹤0.01%
650
-38,500
-98% -$70.9K
EYPT icon
1216
EyePoint Inc
EYPT
$999M
$1K ﹤0.01%
144
LKFT
1217
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$1K ﹤0.01%
51
GLUE icon
1218
Monte Rosa Therapeutics
GLUE
$1.82B
$1K ﹤0.01%
203
HCM icon
1219
HUTCHMED
HCM
$1.96B
$1K ﹤0.01%
85
HUMA icon
1220
Humacyte
HUMA
$168M
$1K ﹤0.01%
301
IRWD icon
1221
Ironwood Pharmaceuticals
IRWD
$586M
$1K ﹤0.01%
573
ITOS
1222
DELISTED
iTeos Therapeutics
ITOS
$1K ﹤0.01%
121
KROS icon
1223
Keros Therapeutics
KROS
$197M
$1K ﹤0.01%
133
LXRX icon
1224
Lexicon Pharmaceuticals
LXRX
$1.03B
$1K ﹤0.01%
1,369
MESO
1225
Mesoblast
MESO
$1.83B
$1K ﹤0.01%
105

Similar funds

Daiwa Securities Group's Q1 2025 Portfolio in Review

As of Q1 2025, Daiwa Securities Group held 1,328 positions worth $23.7B, up 5.6% from $22.4B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Daiwa Securities Group deployed $2.43B of net new capital in Q1 2025, opening 56 new positions and adding to 716 existing holdings. Its largest new stake was Autoliv: 89,727 shares worth $7.94M.

By sector, the portfolio is most concentrated in Real Estate at 35% of assets, down from 38% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was VICI Properties, an estimated $173M trimmed.

  • Daiwa Securities Group's largest Q1 2025 buy was Autoliv: 89,727 shares worth $7.94M.
  • Daiwa Securities Group added most to Apple in Q1 2025, an estimated $229M increase.
  • Daiwa Securities Group's biggest Q1 2025 reduction was VICI Properties, cutting an estimated $173M.
  • Daiwa Securities Group fully exited Global X SuperDividend REIT ETF in Q1 2025, selling an estimated $20.8M.
  • Daiwa Securities Group's ten largest holdings make up 31% of its $23.7B portfolio in Q1 2025.
  • Daiwa Securities Group opened 56 new positions and closed 49 in Q1 2025.
  • Daiwa Securities Group's portfolio value rose 5.6% quarter-over-quarter to $23.7B.

Based on Daiwa Securities Group's 13F filing for Q1 2025, filed 13 May 2025.